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Abstract
Dengue vaccine development has made significant strides, but a better understanding of how

19

vaccine-induced immune responses correlate with vaccine efficacy can greatly accelerate development,

20

testing, and deployment as well as ameliorate potential risks and safety concerns. Advances in basic

21

immunology knowledge and techniques have already improved our understanding of cell-mediated

22

immunity of natural dengue virus infection and vaccination. We conclude that the evidence base is

23

adequate to argue for inclusion of assessments of cell-mediated immunity as part of clinical trials of

24

dengue vaccines, although further research to identify useful correlates of protective immunity is

25

needed.

26

27
28

Introduction
The immunological basis of the efficacy of many of the most well-established vaccines is poorly

29

understood, and, where studies to better understand vaccine efficacy have been done, they have almost

30

always relied on tests of pathogen-specific antibodies rather than on measures of cell-mediated

31

immunity (CMI) [1]. Several reasons likely explain this bias; serum is more easily obtained than viable

32

lymphocytes, antibodies can be studied in isolation, and assays of antibody concentration and function

33

are technically more straightforward and reproducible than cellular assays. Fortunately, in many cases

34

detection of antibodies at or above a defined concentration using specific assays has proven to serve as

35

a useful correlate of protective immunity. However, there has been ample evidence in the case of

36

established vaccines that the information provided by assays of antibody responses is often incomplete,

37

and that protective immunity (sometimes only partially protective) was present in some individuals

38

without protective antibody levels.

39

A consultation was organized by the WHO in 2007 to “review the state of the art of dengue CMI

40

and to discuss the potential role of CMI in advancing dengue vaccine candidates towards licensure” [2].

41

The participants concluded that “precise function of CMI in protection or disease pathology remains ill-

42

defined and, at present, there is no evidence to suggest that CMI can be utilized as a correlate of

43

protection.” Recent data from dengue vaccine trials has renewed interest in addressing this issue,

44

however. In the pivotal phase III trials of the Sanofi Pasteur chimeric dengue virus (DENV) – yellow fever

45

virus (YFV) vaccine, plaque reduction neutralization titers (PRNT) only weakly correlated with protection,

46

and breakthrough infections occurred in some individuals with high PRNT values [3, 4]. While efforts

47

continue to refine assays of DENV-specific antibodies in order to discriminate effective/protective from

48

ineffective/non-protective antibodies (assuming that this is possible), these findings re-emphasize the

49

need to consider the role of DENV-specific T lymphocyte responses in vaccine efficacy. This review seeks

50

to summarize the current state of knowledge regarding DENV-specific CMI and propose potential

51

contributions of CMI measurements to dengue vaccine development and testing.

52

An appraisal of the literature on DENV-specific T cell responses merits a brief review of current

53

paradigms in T cell biology and relevant technologies. One area highlighted by recent work is the

54

complexity of effector T cell subsets. Extending the paradigm of Th1 versus Th2 responses among CD4 T

55

cells, at least 7 different phenotypes have now been described [5, 6]. Table 1 summarizes key proteins

56

expressed by each subset. Cytokines and other signals produced by antigen-presenting cells during the

57

initial T cell activation (not listed in the table) determine which pathway is taken by an individual T cell

58

through the induction of the transcription factors listed, and this in turn controls the profile of

59

chemokine receptors and cytokines produced. The characteristic cytokines produced by each subset are

60

the major determinant of its role in immunity and also tend to reinforce cell polarization. The profile of

61

chemokine receptors expressed by each cell subset determines that subset’s predominant anatomical

62

distribution, such as peripheral versus mucosal versus secondary lymphatic sites, which also contributes

63

to its function in the response to different pathogens. Cytolytic activity, not traditionally considered an

64

important effector function of CD4 T cells, has been increasingly recognized, mainly among cells

65

expressing Th1 cytokines [7]. In contrast, while cytolysis has long been seen as the main function of CD8

66

T cells, there has been a growing recognition of more diverse subsets within this population. CD8 T cell

67

subsets with cytokine profiles similar to several of the CD4 subsets listed in Table 1 have been described,

68

although there is comparably less known about them. Based on studies in mice, T cell polarization has

69

often appeared to be a fixed characteristic of the cell determined during its initial activation. However,

70

studies in humans suggest more plasticity in T cell phenotype [8].

71

Another area of active research in T cell biology is the developmental relationships between

72

naïve, effector, and memory T cells [9-11]. This topic entails significant debate, as, unlike the case with B

73

lymphocytes, there are no universally accepted standards for defining a memory T cell; several different

74

schemas have been proposed to define the phenotypes of effector versus memory T cells, but it is clear

75

that these are imperfect. From a functional standpoint, it is recognized that, among antigen-experienced

76

T cells, there is a subset of short-lived effector cells that are destined to undergo apoptosis whereas

77

other cells demonstrate the capacity for long-term persistence and even self-renewal. Within the long-

78

lived memory cell population, heterogeneity in function and protein expression led to a distinction of

79

central memory T cells (TCM) and effector memory T cells (TEM). Recent data have revealed further

80

complexity, and led to the classification of several additional subsets such as tissue-resident memory T

81

cells (TRM) and stem memory T cells. Rather than fixed cell fates, however, there is evidence that these

82

phenotypes retain some degree of plasticity. The timing and determinants of the transitions between

83

states are not fully understood, and remain an important area of investigation. Several markers have

84

been clearly identified as strongly associated with a cell’s capacity for long-term survival, such as high

85

expression of IL-7R and low expression of KLRG1.

86
87
88

Assay methods
Persisting antibody following vaccination is recognized as the first line of defense against

89

subsequent infection and is regarded as a distinguishing characteristic of an effective vaccine [12]. All

90

currently licensed anti-viral vaccines elicit a robust antibody response that correlates with the level of

91

protection provided by the vaccine [13]. If the same should prove to be true for dengue, then the search

92

for a CMI “correlate of protection” for dengue would be unnecessary. However, dengue is one of several

93

globally important infectious diseases, along with HIV, malaria, and tuberculosis, for which a vaccine is

94

highly desirable yet no validated animal model or correlate of immune protection is known. While

95

empirical testing of candidate vaccines has been successful in the past, the era of molecular biology has

96

led to an explosion of tools and methodologies for creating new vaccine antigens and vector delivery

97

systems. The contribution of CMI, particularly T cells, to a successful dengue vaccine is highly likely

98

whether it be as direct effector cells, provision of help for antibody development or creating a

99

generalized anti-viral environment. Together with the antigenic complexity of candidate dengue

100

vaccines (Table 2), assessing T cell responses presents a logistical problem for both vaccine developers

101

and clinical testing laboratories – how to test or screen for all possible T cell functions when the most

102

relevant function(s) are unknown.

103

Fortunately, T cell-based immunoassay development has also proceeded at a remarkable rate

104

[14, 15]. A list of assays together with their advantages and disadvantages is presented in Table 3.

105

Recently the focus of immune-monitoring has been upon assays that provide “minimal manipulation.”

106

Relatively high-throughput assays such as ELISPOT and intracellular cytokine staining (ICS), which utilize

107

in vitro stimulation times of less than 24 hours (or no stimulation in the case of direct ex vivo flow

108

cytometry), are the assays of choice as a screening tool. When well qualified, both platforms are

109

quantitative and specific for the antigen. While validation of ELISPOT and ICS assays is not trivial, it is

110

possible, and if a T cell-based correlate of protection for dengue is defined one of these platforms would

111

most likely be the basis of such an assay [16, 17]. The general disadvantage of ELISPOT assays is that

112

some a priori knowledge of the relevant functions is required. IFN- has been used extensively in vaccine

113

development as a marker of vaccine take and as a function that is necessary, but perhaps not sufficient,

114

for protection. ICS expands upon the functional profile of ELISPOT assays, bringing the concept of

115

polyfunctionality of T cells to the fore. Again, some a priori knowledge of the relevant functional profile

116

is required to fully interpret the results of this assay. Furthermore, ELISPOT and ICS assays are best

117

suited for measuring and quantifying the direct effector capacity of T cells (IFN-, TNF, and cytolytic

118

potential), but are significantly less sensitive at measuring T cell helper capacity. Mass cytometry and

119

advanced polychromatic flow cytometry are technologies that permit the analysis of as many as 36

120

parameters simultaneously on a single cell. These parameters may include both phenotypic and

121

functional markers. While these methods will facilitate high-dimensional, quantitative analysis of

122

biomolecules on cell populations at single-cell resolution, their application to dengue research has so far

123

been limited [18, 19].

124

The most sensitive assays are generally those that involve proliferation of a small number of

125

antigen-specific precursor cells. Dye-dilution based T cell proliferation, when appropriately calibrated,

126

can identify the phenotype of proliferating T cells as well as quantify the precursor frequency [20]. In

127

addition, cytokines associated with helper (e.g., IL-4, IL-5, IL-13, IL-21) or regulatory (e.g., IL-10, TGF-)

128

capacity can be studied in supernatants collected from proliferation assays. This approach does however

129

digress from the minimal manipulation concept, is less reproducible and is prone to in vitro variation

130

artifact.

131

Microfluidics-based technologies have led to the possibility of extensive transcriptional profiling

132

of T cells at the single-cell level and a description of the population dynamics of T cell responses. While

133

better suited to a research-based environment, these methodologies provide a discovery platform that

134

will deliver the best opportunity to uncover a correlate of protection [21, 22]. Ultimately a thorough

135

profiling of the entire “immune space” that is occupied by a dengue vaccine will be required to compare

136

and contrast different vaccine modalities and vaccination strategies [23]. Describing the quality, quantity

137

and durability of immune responses elicited will involve a standardized approach incorporating many of

138

assay procedures listed above and probably new technologies as they become deployable.

139

Should a CMI correlate of protection from dengue infection be identified, a significant effort will

140

be required to qualify and validate assays platforms that will reliably detect and/or measure the

141

correlate or function. As described earlier, validation of ELISpot or ICS format assays has proved

142

possible; however, the further challenge will be applying these assays to meet the needs of the global

143

dengue vaccine research community. The field would benefit from the establishment of centralized

144

laboratory(s) that implement External Quality Assurance (EQA) Programs for overseeing the

145

development of external proficiency testing programs for flow cytometry, ELISpot and other CMI-based

146

assays [24-27]. EQA programs serve three purposes and are run according to Good Clinical Laboratory

147

Practice (GCLP) guidance: 1) provide a means for laboratories to ensure that the data generated are

148

accurate, timely and clinically relevant; 2) provide assurance to sponsors that the data is reliable and

149

high quality; and 3) ensure the appropriate and accurate use of human specimens obtained from clinical

150

trials. In addition to EQA programs, the establishment of biorepositories of standardized qualified

151

reagents and antigens (e.g. PBMCs, peptide sets, viral isolates) for use in helping laboratories validate

152

assays would be invaluable [28-30]. Such programs have proved successful for the field of HIV vaccine

153

testing, with the EQAPOL program run by the NIH Division of AIDS, and the field of cancer T cell therapy,

154

with the immunomonitoring program run by the Cancer Immunotherapy Consortium

155

(http://www.cancerresearch.org/cic) [24, 31, 32].

156
157
158

T cell responses to DENV
Human T cell responses to DENV were first characterized over 30 years ago, and many of the

159

general principles originally described have remained consistent [33, 34]. Infection with one DENV

160

induces both CD4 and CD8 memory T cells specific for DENV epitopes, with a small number of epitopes

161

dominating the response in each individual. Epitopes are located throughout the DENV polyprotein,

162

although several regions, especially the nonstructural protein 3 (NS3), appear to have a concentration of

163

immunodominant epitopes. The amino acid homology across the four DENV serotypes varies for each

164

epitope; however, most epitopes are well conserved among strains within the same serotype and differ

165

at relatively few positions (1 to 3 of 9 residues) from the corresponding epitopes of other DENV

166

serotypes (and other flaviviruses). The overall T cell response induced by a primary DENV infection is

167

strongest to the serotype to which the subject had been exposed, but variable degrees of cross-

168

reactivity are usually observed to one or more of the other serotypes.

169

Notwithstanding the confirmation of the above paradigms, the greater understanding of T cell

170

biology and advancements in techniques for analysis of T cell responses described above have provided

171

a more detailed and complex picture, particularly with regard to the different characteristics of the

172

memory T cell response and their potential functions during the recall response to a subsequent DENV

173

infection. Inasmuch as vaccination is intended to induce an immune response that will protect against

174

infection or disease during a subsequent DENV exposure, these findings are highly relevant to evaluating

175

the immunogenicity of different vaccine regimens. However, extrapolating observations from natural

176

DENV infection to current vaccines is confounded by several important differences, as will be discussed

177

further below.

178
179
180

Survey of recent literature
The pace of scientific publications describing the T lymphocyte response to DENV has greatly

181

accelerated in recent years. A review of PubMed entries showed at least 38 papers published since 2005

182

that analyzed human DENV-specific T cell responses based either on functional responses to stimulation

183

by DENV antigens or staining by HLA-peptide tetramers containing DENV peptides, 26 of which have

184

been published since 2010 [35-75]; papers that measured serum levels of cytokines or frequencies of

185

lymphocyte subsets during acute DENV infection were not counted if the methods could not relate the

186

findings with antigen specificity. Taking advantage of newer techniques, these papers have greatly

187

expanded the number of individuals whose immune responses have been characterized- tens to

188

hundreds of subjects in each study, in comparison to fewer than 10 in most of the earlier studies. The

189

knowledge base of DENV-specific immune responses is thus more representative of the global

190

population, particularly among populations in dengue-endemic areas.

191
192

Several methodological trends are evident in the recent literature. ELISPOT and flow cytometry
have become preferred assays; relatively few of the results from these assays- usually only for dominant

193

responses- have been validated by analysis of epitope-specific T cell lines. All ELISPOT and cytokine flow

194

cytometry studies have examined the production of IFN-. Studies using cytokine flow cytometry have in

195

addition measured several other effector functions, in particular TNF, MIP-1, or IL-2 production or

196

release of cytotoxic granules (measured by capture of CD107a at the cell surface).

197

In vitro stimulation for detection of DENV-specific T cells was accomplished with synthetic

198

peptides in nearly all of the recent studies. In comparison with crude antigen preparations used in

199

earlier studies, such as DENV-infected cell lysates, synthetic peptides provide greater standardization

200

and reproducibility, and also directly provide detailed epitope localization. The large number of peptides

201

needed to provide a comprehensive analysis of all potential DENV epitopes presents a major technical

202

challenge, however. None of the studies reviewed included overlapping peptides from the full

203

proteomes of all four DENV serotypes. Weiskopf et al conducted the most comprehensive analysis [60];

204

however, although a total of 8,000 peptides were used in the study, each subject was only tested for

205

recognition of a subset of peptides selected based on predictions of peptide binding to autologous HLA

206

class I alleles. Epitope prediction algorithms were used in 8 other studies, but many fewer candidate

207

epitopes were tested. Fourteen studies tested sets of overlapping peptides; of these, 4 studies tested

208

peptides covering the full proteome of DENV-2, whereas the remaining studies tested overlapping

209

peptides covering only a portion of the proteome, most often the NS3 protein.

210

At least 10 studies have used HLA-peptide tetramers to analyze DENV-specific T cells either

211

directly ex vivo or after in vitro expansion [36, 38, 42, 47-49, 52, 59, 66, 73]. However, six of these

212

studied the same HLA-A*1101-restricted “GTS” epitope on the NS3 protein; in total, the remaining 4

213

studies investigated 5 other CD8 T cell epitopes and 2 CD4 T cell epitopes. Thus, conclusions based on

214

this body of data still are subject to considerable potential for bias.

215

216

Contributions from animal models

217

Differences between study populations in host genetics as well as prior DENV exposures

218

continue to complicate the comparison of findings across studies. Given the difficulty in documenting or

219

controlling these factors, there continues to be substantial interest in experimental animal models,

220

particularly small, genetically defined animals such as mice. Several “humanized” mouse models have

221

been studied. In several studies of transgenic mice expressing single HLA alleles, investigators

222

demonstrated recognition of candidate epitopes that were selected for predicted HLA binding;

223

subsequent testing of DENV-immune humans confirmed responses to some but not all of these epitopes

224

[64, 69, 76-78]. Studies of immunodeficient mice in which human immune cells were reconstituted by

225

transfusion of human hematopoietic stem cells detected T cell responses to a limited number of known

226

human T cell epitopes [79, 80]. These studies provide preliminary evidence that these models might

227

supplement human studies. Limited testing of heterologous secondary DENV infections was done in

228

HLA-transgenic mice [78], but no comprehensive analysis of the different possible sequences of DENV

229

infection has been conducted in these models to date.

230
231
232

Epitope distribution and cross-reactivity
Recent studies have greatly expanded the database of T cell epitopes identified on DENV

233

proteins [81]. This reflects the combined effects of studying a larger number of humans with more

234

diverse HLA alleles and prior DENV infection history as well as the application of single-cell assays such

235

as ELISPOT with large numbers of synthetic peptides. It is difficult to directly compare the results from

236

different studies, however, because of the confounding effects of differences in the numbers and

237

characteristics of the peptides used. Overlapping peptides covering over 70% of the proteome of

238

representative strains of all four DENV serotypes have been made available to the research community

239

through an NIAID-funded reagent repository (www.beiresources.org), but these were not used in most

240

of the published studies. Additionally, there remains a lack of consensus on the optimal criteria for

241

defining epitopes. Immunodominant epitopes- those that induce responses of high magnitude in the

242

majority (often nearly all) of subjects with the appropriate HLA allele- have generally shown similar

243

results across studies, but these represent a minority of the epitopes identified and the generalizability

244

of the observations regarding these epitopes needs to be verified.

245

As mentioned above, the distribution of T cell epitopes across all DENV proteins, albeit with a

246

predominance of epitopes on nonstructural proteins, has been reinforced by the expanded literature. A

247

need to test for responses to the entire proteome of all four DENV serotypes presents challenges for

248

performing large-scale testing of T cell responses, such as in the context of a phase II or III vaccine trial.

249

In contrast, data pointing to the immunodominance of responses to particular regions of the polyprotein

250

provide some support for more targeted testing. For example, Weiskopf et al have estimated that a pool

251

of 268 peptides would include 90% or more of CD8 T cell epitopes in any study population [72].

252

However, this conclusion is based on their approach of HLA class I epitope prediction. It is reasonable to

253

hypothesize that other immunologically important epitopes, especially HLA class II-restricted epitopes,

254

have yet to be defined. Studies have yielded conflicting data on whether the distribution of CD4 T cell

255

epitopes is similar or different from that of CD8 T cell epitopes [48, 57], with one study reporting that

256

CD4 T cells more often recognized epitopes on structural proteins [57].

257

The use of single-cell assays such as ELISPOT has complicated the interpretation of serotype-

258

cross-reactivity of T cell responses, as these assays do not assess serotype-cross-reactivity at the level of

259

individual cells. This is a particular problem in individuals who have been exposed to more than one

260

DENV serotype, either through sequential exposure or multivalent immunization. Although one study

261

concluded that serotype-specific epitopes could be defined based on sequence conservation alone [78],

262

other experimental data are directly contradictory [36, 37, 41]. Another study described a panel of CD4

263

T cell epitopes predicted to be serotype-specific based on high sequence divergence across serotypes

264

[55]. Among participants in a cohort study, individuals who experienced an interval DENV infection

265

acquired responses to peptides of one additional serotype [74]; however, only 7 subjects were studied

266

and the DENV serotype causing the interval infection was not identified.

267

Several recent findings underscore the importance of clinical, virologic, and epidemiologic data

268

on individual subjects for the interpretation of T cell responses to DENV. Although measures of T cell

269

responses at the population level consistently show stronger responses to the infecting DENV serotype

270

after a primary DENV infection, exceptions to this pattern have been observed at the level of individual

271

epitopes [37, 49, 52], and the patterns of cross-reactivity have been even more difficult to predict after

272

secondary DENV infections. Several studies have also found sufficient sequence divergence within one

273

or more DENV serotype(s) to affect the T cell response [67, 82], but the clinical significance of these

274

observations is unknown.

275
276
277

T cell subsets and their effector functions
Recent studies using multiparameter flow cytometry have provided a more detailed picture of

278

the effector T cell response to DENV. As noted above, most studies have focused on type 1 cytokine-

279

producing T cells (Th1/Tc1); these studies have revealed a high degree of heterogeneity in cytokine

280

production at the individual cell level. While polyfunctional T cells expressing 3 or more effector

281

functions have been observed, there are also substantial populations of cells expressing 1 or 2 of the

282

functions measured, including cells expressing only cytokines with pro-inflammatory effects (TNF

283

and/or -chemokines) [37, 49, 60, 67]. Stimulation with the corresponding epitopes of different DENV

284

serotypes has been shown to alter the profile of cytokines produced, suggesting that variant epitopes

285

act as altered peptide ligands for some DENV-specific T cells [36, 37].

286
287

Comparably less is known regarding effector responses other than Th1/Tc1. Of the few studies
that reported data on the production of type 2 cytokines, most reported little or no production of IL-4

288

except one study of very young children (mean age 7.7 months) [61]. Single studies have described

289

production of IL-17 [61] or IL-21 [57] by T cells in response to stimulation, or have observed the

290

expression of markers associated with follicular helper CD4 T cells [57] or T cells capable of homing to

291

skin [73].

292
293

Primary vs. secondary infection

294

Models of sequential infection with different DENV serotypes postulate that the immune

295

response to secondary infection will differ in several important ways from that to the primary infection:

296

a) the memory T cell response will be induced more rapidly and achieve higher levels, b) the memory

297

response will preferentially activate T cells directed at epitopes that are more highly conserved between

298

the different DENV serotypes, mainly on non-structural proteins, and c) the memory T cell response will

299

have an altered effector profile reflecting differential activation by peptides from the second DENV

300

serotype [83]. Although testing these postulates is highly relevant to understanding both protective and

301

detrimental immune responses in dengue, only a few studies have compared immune responses during

302

or after primary versus secondary DENV infections. Consistent with the predictions, differences have

303

been reported in the expression of some phenotypic markers [71], in the dominant epitopes targeted

304

[78], and in the profile of serotype cross-reactivity [52, 82]. Surprisingly, no significant differences were

305

observed in the kinetics of the response or in the peak T cell frequencies during the acute infection [48,

306

52]. These studies involved only symptomatic DENV infections, however, and the intrinsic incubation

307

period prior to the onset of symptoms could not be determined. Also, the clearance of viremia may be

308

more rapid in secondary infections, as suggested by some data [84]. These significant differences could

309

have masked differences in the kinetics and magnitude of the immune response in primary versus

310

secondary infections.

311

312
313

Vaccines vs. natural infection
With the expanding pipeline of vaccines in clinical testing and the wider availability of the

314

requisite expertise and technology, there has been a growing body of literature describing the T cell

315

response to dengue vaccines. All of the recently published studies have involved candidate live

316

attenuated vaccines. These studies have shown that DENV-specific memory T cells, including

317

polyfunctional Th1/Tc1 cells, are induced within 21 days after vaccination of flavivirus-naïve subjects

318

[56]. In comparison to vaccination with its individual components, vaccination with the tetravalent

319

formulation of the NIH/Butantan vaccine (Table 2) preferentially induced T cell responses to peptides

320

from the more conserved non-structural proteins [70]. Interestingly, vaccination with the Sanofi Pasteur

321

chimeric DENV-YFV vaccine induced T cell responses to epitopes on DENV NS3 protein in DENV-immune

322

subjects but not in DENV-naïve subjects, suggesting that the heterologous YFV epitopes could reactivate

323

pre-existing memory CD8 T cells but not antigen-inexperienced T cells [62]. Comparison of the T cell

324

responses induced by the different dengue vaccines listed in Table 2 is not possible, however, because

325

of significant differences in study and assay design.

326
327
328

Potential contributions of T cell assays to dengue vaccine development
The area where assessment of T cell responses to dengue vaccines would clearly have greatest

329

impact is in identifying correlates of vaccine efficacy. A reliable immunological correlate of vaccine-

330

induced protective immunity would accelerate vaccine testing in different populations, regimens, or

331

epidemiological contexts. The limitations of current neutralizing antibody assays reinforce the need for a

332

better understanding of correlates of protective immunity, although the poor discriminant ability of

333

neutralizing antibody titers may point either to deficiencies in the assay or to non-antibody protective

334

mechanisms. Human cohort studies and animal experiments have found associations between T cell

335

IFN- production and protective immunity [51, 60, 85, 86], supporting the potential to identify T cell

336

responses associated with protective immunity induced by vaccination. However, the published data are

337

quite limited. Only two studies correlated T cell responses in blood samples collected prior to exposure

338

with clinical outcomes in individual subjects [51, 87]; both studies relied on the same prospective cohort

339

and the sample sizes were small. Also, given the difficulty in defining individuals who are fully protected

340

from infection, all subjects in these studies experienced DENV infections and comparisons were based

341

on severity of illness (hospitalized dengue versus non-hospitalized dengue in one study and subclinical

342

versus symptomatic infection in the other). Other studies measured T cell responses only during or after

343

DENV infection, a significant confounding factor for any conclusions regarding causality. This concern is

344

somewhat lessened in the case of experimental infection, where protective immunity was associated

345

with early IFN- responses [88]. In light of the limitations of published data, however, it will be essential

346

to validate immunological correlates against clinical endpoints in vaccine trials.

347

It will be important to validate any immunological correlates independently for several different

348

vaccines, because the associations between immunological readouts and vaccine efficacy may or may

349

not be equivalent. In addition to the differences in immune response pathways that might be stimulated

350

by live versus inactivated or subunit vaccines, there are significant differences in antigenic content

351

among the dengue vaccines currently in clinical development (Table 2). This is most pronounced with

352

regard to the repertoire of flavivirus non-structural (NS) proteins, with some vaccines containing no NS

353

proteins (subunit and inactivated vaccines, although the latter may include some NS1 protein), some

354

containing NS proteins of one flavivirus, either DENV2 or the heterologous YFV, and one containing NS

355

proteins of 3 of 4 DENV serotypes. Since non-structural proteins contain the majority of T cell epitopes,

356

the repertoire of T cell responses induced by each vaccine will likely differ as well, although the resulting

357

immunological profile is difficult to predict at this stage.

358
359

A second area where measurement of T cell responses could make an important contribution is
in evaluating the durability of vaccine-induced protective immunity. This is likely to be of particular

360

importance for dengue vaccines given the evidence that partial immunity increases the risk for more

361

severe illness. Substantial insight has been gained into how the initial activation of T cells contributes to

362

the establishment of both long-lasting T cell and B cell memory, and this process has been successfully

363

manipulated with pharmaceuticals such as rapamycin in experimental models [89, 90]. Licensed

364

vaccines against other diseases differ significantly in the durability of pathogen-specific antibodies and T

365

cells [91]; through comprehensive “systems vaccinology” approaches, early indicators of antibody and T

366

cell responses have been identified for several of these vaccines [92, 93], although further studies are

367

needed to establish their ability to predict longer-term durability of the response.

368

The single-cell resolution and potential to evaluate multiple T cell effector functions of newer

369

assays offer the capacity to reveal extraordinary detail on the relationships between these responses.

370

This capacity will likely be of special interest in the case of dengue vaccines, given the multivalent nature

371

of dengue vaccines, the need to provide protective immunity against all four DENV serotypes, and the

372

evidence that more severe dengue disease is associated with an inflammatory immune response. Data

373

from several studies showing the induction of polyfunctional T cells by different tetravalent dengue

374

vaccines are encouraging [56, 70, 75]. However, it is unclear whether the degree of ‘polyfunctionality’

375

described is optimal; similar frequencies of polyfunctional T cells are seen after natural DENV infection, a

376

setting that does not reflect fully (i.e., tetravalent) protective immunity. Partial immunity to DENV

377

present prior to vaccination, as was seen in the majority of subjects in phase III vaccine trials in endemic

378

areas [3, 4], could also modify the pattern of T cell effector functions.

379
380
381

Conclusions and recommendations
Although assessments of pathogen-specific T cell responses have not been a priority in most

382

vaccine development efforts, we argue that dengue is a special case and that planning and preparation

383

for such assessments should be given greater emphasis. The example of natural infection illustrates the

384

potential for both positive (protective) and negative (pathological) effects of partial immunity to DENV,

385

and potential concerns for long-term safety will likely remain a major impediment to licensure and

386

widespread uptake of dengue vaccines. The current understanding of T cell responses to DENV indicates

387

the potential for evaluations of T cell responses to accelerate vaccine design and testing by helping to

388

identify correlates of vaccine efficacy and also to reduce the risk to vaccine developers by helping to

389

understand negative outcomes of vaccine trials, should they occur [94]. Implementing analyses of T cell

390

responses in the context of upcoming dengue vaccine trials will present a number of significant logistical

391

challenges (Table 4). Based on current knowledge, it is not possible to define the assay or assays that

392

would reliably serve all of the pertinent objectives. The experience from prospective dengue cohort

393

studies [51, 87] and trials of other vaccines [95] does provide guidance to vaccine developers as to how

394

T cell studies can be incorporated into dengue vaccine trials. There continues to be a need for studies of

395

natural DENV infection as well as efforts to develop new technologies for assessment of T cell responses

396

to DENV. Implementation of these efforts will require ongoing support from government, industry, and

397

charitable foundations, as well as creative solutions from the scientific community.

398

399
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Table 1. Characteristics defining different subsets of effector CD4 T cells.
Subset

Cytokine(s)

Chemokine

Transcription

produced

receptor(s)

factor(s)

Comment

Th1

IFN-

CXCR3

T-Bet

Cellular immunity

Th2

IL-4, IL-5, IL-13

CCR3, CCR4,

GATA-3

Humoral immunity

RORt

Inflammation

PU.1

Mucosal immunity

CCR8
Th17

IL-17

CCR2, CCR4,
CCR6

Th9

IL-9

CCR3, CCR6,
CXCR3

662
663

Th22

IL-22

CCR4, CCR10

AhR

Parasites

Tfh

IL-21

CXCR5

Bcl-6

B cell help

iTreg

IL-10, TGF-

CCR6

FoxP3

Immunosuppression, tolerance

664

Table 2. T cell antigenic content of dengue vaccine candidates in clinical development.
Vaccine developer

Structural proteins

Non-structural proteins

Live, attenuated (chimeric
flaviviruses)
Sanofi Pasteur

C: YFV; pre-M, E: DENV1-4

NS1-5: YFV

Takeda

C: DENV2; pre-M, E: DENV1-4

NS1-5: DENV2

NIH/Butantan

C: DENV1/3/4; pre-M, E: DENV1-

NS1-5: DENV1/3/4

4
Purified inactivated
WRAIR/GSK

C, pre-M, E: DENV1-4

None (? NS1)

E (80%): DENV1-4

None

Subunit
Merck
665
666

667

Table 3. Advantages and disadvantages of different methodologies for evaluation of pathogen-specific T

668

cell responses.
Method

Functions measured

Advantages

Disadvantages

Ex vivo (no stimulation)
Flow cytometry (HLApeptide tetramer

Antigen specificity
Phenotype

staining)

Quantitative readout of
cell frequency
Independent of cell
responsiveness

Limited to one or few
epitopes
Not reflective of cell
function
Costly

Short-term in vitro (1
day)
Flow cytometry/mass
cytometry
(intracellular
staining)
ELISPOT

Cytokine production

Quantitative readout of

Degranulation

cell frequency

(cytolysis)

Multiple functions

Phenotype
Cytokine secretion
Granzyme release

Costly
Specimen requirement
high

assessed
Quantitative readout of
cell frequency
Technical ease
Reproducibility
Specimen requirement
low/modest

One (or two) functions
assessed per cell

Single-cell
transcriptional
profiling

Any function (based on
gene expression)
Gene networks
controlling cell fate

Provides complete

Technically complex

profiling at the

Low throughput

single-cell and

Expensive

population level

Data analysis requires
bioinformatics
expertise

Extended in vitro (5+
days)
ELISPOT

Cytokine secretion

High sensitivity

Granzyme release

Technical ease
Specimen requirement
low/modest

Flow cytometry (marker

Proliferation

dilution)
3

H-Thymidine

High sensitivity

One (or two) functions
assessed per cell
Cell frequency altered
by stimulation
Less reproducible

Technical ease
Proliferation

incorporation

High sensitivity

Radioisotope

Low cost

Less reproducible

Technical ease
Immunoassay

Cytokine secretion

Technical ease

Granzyme release

Can be multiplexed

Low sensitivity for rare
cells

Cloning (characterize
with other assays)

Multiple

Multiple functions
measured
Evaluates antigen
crossreactivity

669
670

Low throughput (few
cells evaluated)
Costly
Technical complexity
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Table 4. Logistical issues and recommendations for assessment of T cell responses to dengue vaccines.
Issues
Technical expertise and infrastructure needed for
collection of viable PBMC
Need to measure responses to all four DENV
serotypes (and separately for structural

Recommendations
Study site development and staff training and
supervision
Collect adequate volumes of blood for assessment
of T cell responses

and non-structural antigens)
Immune correlates of vaccine efficacy have not yet
been defined
Variation in HLA alleles and prior DENV exposure
history in vaccine recipients

Apply a diverse suite of assays of T cell function
and specificity
Enroll adequate numbers and diversity of subjects
in assessments of T cell responses to
vaccination
Collect blood samples before and after vaccination
for T cell assays

Lack of high-throughput assays to measure crossreactivity at single-cell level
672

Development of new assay technologies

